Landmark Research: The ANCHOR Study
The Anal Cancer/HSIL Outcomes Research (ANCHOR) Study was a landmark randomized clinical trial evaluating whether treatment of anal high-grade squamous intraepithelial lesions (HSIL) could prevent progression to anal cancer in people living with HIV.
The study demonstrated that treatment of anal HSIL significantly reduced the risk of progression to anal cancer compared with active monitoring, providing important evidence supporting the treatment of anal HSIL as a strategy to prevent anal cancer.
The ANCHOR Study was led by Dr. Joel Palefsky of UCSF and conducted through a national network of clinical research sites.
Study status: Completed
Published Results
Palefsky JM, et al.
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.
The New England Journal of Medicine. 2022.
Read the ANCHOR Study publication in The New England Journal of Medicine